Physician profile
Patrick N Ciccone
NPI 1477576643
$1,270.90
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $128 · 2021: $445 · 2022: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $322.16 | 2019-2022 | |
| Boston Scientific Corporation | $161.13 | 2019-2021 | |
| Teleflex LLC | $134.99 | 2022 | |
| Procept Biorobotics Corporation | $123.76 | 2021 | |
| Amgen INC. | $108.45 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $63.48 | 2019-2021 | |
| Janssen Biotech, INC. | $58.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $53.54 | 2019 | |
| Abbvie INC. | $44.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.94 | 2019-2020 | |
| Medtronic USA, INC. | $27.01 | 2019 | |
| Allergan, INC. | $26.71 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $26.06 | 2019-2020 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Pfizer INC. | $14.36 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $14.03 | 2021 | |
| Dendreon Pharmaceuticals LLC | $13.97 | 2019 | |
| Royal Biologics, INC. | $11.53 | 2020 | |
| Aytu Biopharma, INC. | $11.15 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ciccone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.